Kazia Therapeutics (KZIA) said Tuesday that data showed its paxalisib therapy significantly reduced tumor burden and the total amount of cancer in the body by 52% in a preclinical model of ...
Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in ...
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity ...
Kazia Therapeutics (KZIA) said Tuesday that it will expand its ongoing paxalisib clinical trial into hormone receptor-positive, HER2-negative advanced breast cancer after preclinical data showed ...
Biologic therapy may alter the gut microbiome in patients with autoimmune arthritis, with specific microbial patterns linked to treatment response.
Juniper Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole, or FMISO), the first-in-class ...
A type C meeting between IDEAYA Biosciences and the FDA has established the design of a phase 3 registrational trial for ...
When added to standard chemotherapy, a clinical version of the dietary supplement L-glutamine improved survival in an ...
Bored Panda on MSN
Medical professionals share the diagnoses that made their stomachs drop
Healthcare workers have an incredibly important job, helping us through illnesses, injuries, and some of the hardest times in ...
PMV Pharma's rezatapopt achieves 44% response rate in TP53 Y220C ovarian cancer patients, positioning the drug for potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results